StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
0332.KL$0.15+0.00%
Fair $0.15+0.0%

0332.KL

Topvision Eye Specialist Berhad

Healthcare / Medical Care FacilitiesKuala Lumpur

$0.15

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $0.15Fund rank 28/100 · Data gapFallback financials|
SA 37/D
F-Score: 5/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 22%

FCF escenarios

weak_data · normalized FCF $1.3M · quality 46.3/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 29/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

37/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is 4.7%, below the 5% threshold
Thesis & Journal · 0332.KLLocal privado en este navegador · Topvision Eye Specialist Berhad
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$48M

P/E

N/A

•

EV/EBITDA

5.6x

↓

ROE

4.7%

↑

Gross Margin

49.9%

↑

Debt/Equity

0.65

↑
52-Week Range$0
$0$0

TradingView lightweight chart

0332.KL price, volumen y niveles de valoración

Último $0.155Periodo -32.6%
Fair value: $0.155

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+5.1%

FCF CAGR

-28.7%

FCF margin

2.9%

FCF / Net income

0.67x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $45.8M · net income $2.0M · FCF $1.3M

2022-FY → 2025-FY

Gross margin

49.9%-1.0% pts

Operating margin

10.9%-13.4% pts

Net margin

4.3%-11.2% pts

FCF margin

2.9%-6.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$45.8M$45.8M$44.2M$43.0M$39.5M
Net Income$2.0M$2.0M$1.0M$4.8M$6.1M
EBITDA$11.6M$11.6M$9.6M$12.4M$11.1M
EPS——0.000.020.02
Gross Margin49.9%49.9%51.2%49.4%50.9%
Operating Margin10.9%10.9%10.5%19.0%24.2%
Net Margin4.3%4.3%2.3%11.2%15.5%
Balance Sheet
Debt/Equity0.650.650.570.570.64
Current Ratio4.024.02———
Cash Flow
Free Cash Flow$1.3M$1.3M$-3.9M$3.3M$3.7M
Returns
ROE4.7%4.7%2.2%16.4%22.9%
Valuation
P/E——89.7140.5434.88
EV/EBITDA5.605.609.8716.2518.18
P/B1.121.121.676.527.18
Growth & Yield
Revenue Growth3.7%3.7%2.9%8.9%—
EPS Growth——-81.6%-14.0%—
Dividend Yield12.9%12.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -19.7%

Total return

-19.7%

Start / end P/E

n/dx → n/dx

EPS bridge

0.00 → n/d

Residual

-32.6%

EPS growthn/d
Multiple reratingn/d
Dividend+12.9%
Residual / FX / buybacks / cross-term-32.6%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.